{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:57:37Z","timestamp":1790351857473,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","bbmt.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.bbmt.2016.06.026","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T18:46:26Z","timestamp":1467398786000},"page":"1861-1866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["T Cell\u2013Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation"],"prefix":"10.1016","volume":"22","author":[{"given":"Jessica","family":"Gorgeis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelin","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence E.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Kent","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.06.026_bib0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbmt.2010.12.713","article-title":"National Cancer Institute's first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: summary and recommendations from the organizing committee","volume":"17","author":"Bishop","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/ehm.10.32","article-title":"Relapse after allogeneic stem cell transplantation","volume":"3","author":"Barrett","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0025","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V82.8.2310.2310","article-title":"Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose","volume":"82","author":"Drobyski","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14712598.2011.554811","article-title":"Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Roddie","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0035","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0040","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bmt.2008.255","article-title":"Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant","volume":"42","author":"Shaw","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0045","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbmt.2015.11.012","article-title":"Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the Grupo Espanol de Trasplante Hematopoyetico","volume":"22","author":"Orti","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0050","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/bmt.2014.83","article-title":"Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation","volume":"49","author":"Tischer","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0055","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbmt.2015.09.002","volume":"22","author":"Bashey","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0065","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0070","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0075","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0080","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0090","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0095","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0100","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbmt.2015.03.003","article-title":"Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0105","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0110","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0115","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0120","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/bmt.2016.62","article-title":"Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation","volume":"51","author":"Solh","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0125","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","article-title":"Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change","volume":"31","author":"Christopeit","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0130","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0140","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.06.026_bib0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116301926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116301926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T06:16:46Z","timestamp":1600841806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116301926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1083879116301926"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.06.026","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T Cell\u2013Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}